What is Oaktree Specialty Lending's deferred offering costs?

Oaktree Specialty Lending (OCSL) reported deferred offering costs of $33K in Q4 2025.

What does deferred offering costs mean?

Reflects the value of costs associated with issuing equity that are settled through non-cash consideration or deferred arrangements. Monitoring these costs helps investors assess the efficiency of capital raising activities and the impact of equity issuance on overall shareholder dilution.

Oaktree Specialty Lending OCSL Deferred offering costs

Deferred offering costs at other companies

Evommune EVMN

-$577.47K—

Sonida Senior LivingSNDA

$0—

Nurix Therapeutics, Inc.NRIX

$100K0.0%

Bain Capital Specialty FinanceBCSF

$3.29M-24.2%

Mineralys Therapeutics, Inc.MLYS

$200K-33.3%

AMB

Ambiq Micro, Inc.AMBQ

-$75K—

Other financials

Income statement

See full

Net income-$18.9M+47.9%

EPS (diluted)-$0.21+50.0%

Balance sheet

See full

Cash & equivalents$51.3M-52.6%

Total debt$1.5B+2.3%

Total equity$1.4B-6.3%

Total assets$2.9B-6.0%

Cash flow

See full

Operating cash flow$130.7M+111%

Valuation

See full

Market cap$1B-16.8%

Enterprise value$2.43B-4.4%

P/E20.2×-113×

Returns & leverage

See full

Return on equity3.5%+2.9pp

Debt / equity1.1×+0.1×

Where this comes from

Reported directly by Oaktree Specialty Lending in its filing.

Tagged under the XBRL concept ocsl:PaymentsOfStockIssuanceCostsNonCash.

The official record: Oaktree Specialty Lending’s 10-Q, filed February 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oaktree Specialty Lending's deferred offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oaktree Specialty Lending's deferred offering costs?: Oaktree Specialty Lending (OCSL) reported deferred offering costs of $33K in Q4 2025.
What does deferred offering costs mean?: Reflects the value of costs associated with issuing equity that are settled through non-cash consideration or deferred arrangements. Monitoring these costs helps investors assess the efficiency of capital raising activities and the impact of equity issuance on overall shareholder dilution.